2020 American Transplant Congress
Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-institutional Study Of > 3000 Patients
*Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC…2020 American Transplant Congress
Performance of the Retreat Score in Predicting Post-Transplant Hepatocellular Carcinoma Recurrence at a Large Academic Center
Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: Post-transplant hepatocellular carcinoma recurrence (R-HCC) results in poor outcomes. The RETREAT score was recently derived to predict HCC recurrence, incorporating pre-transplant alpha fetoprotein and…2020 American Transplant Congress
The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma
1The Cleveland Clinic, Cleveland, OH, 2Duke University, Durham, NC, 3Chiba University, Chiba, Japan
*Purpose: The recurrence rate after liver transplant (LT) for hepatocellular carcinoma (HCC) is high as 15-20% nevertheless of complete removal of tumor and carcinogenic liver.…2020 American Transplant Congress
Multiple Downstaging Episodes for Hepatocellular Carcinoma Prior to Liver Transplant Increases Risk of Post-Transplant HCC Recurrence
Henry Ford Hospital, Detroit, MI
*Purpose: Early-stage Hepatocellular Carcinoma (HCC) is best managed with liver transplantation (LT). Several studies have shown that patients meeting Milan or successfully downstaged to meet…2020 American Transplant Congress
National Experience with Living Donor Liver Transplant for Hepatocellular Carcinoma
1Dept of Medicine, UCSF, San Francisco, CA, 2Dept of Surgery, UCSF, San Francisco, CA
*Purpose: LDLT is an attractive option to decrease both wait time and risk of waitlist dropout in HCC. This study aimed to evaluate temporal and…2020 American Transplant Congress
HCC Liver Transplantation Waitlist Dropout Rates before and after the Mandated Six-Month Wait-Time
*Purpose: Studies have shown significant improvement in hepatocellular carcinoma (HCC) recurrence rates following the UNOS implementation of a six-month wait period. However, few have examined…2020 American Transplant Congress
Comparing Post-Transplant Outcomes in Living and Deceased Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: An Analysis of UNOS Registry
*Purpose: Because of possible short waiting time, living donor liver transplantation (LDLT) for HCC may provide survival benefit compared to deceased donor LT (DDLT). This…2019 American Transplant Congress
Treatment Modality Affects Outcomes of Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A US Multicenter Analysis of 2786 Patients
*Purpose: Recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) has a poor prognosis. We evaluated the impact of treatment modalities on post-recurrence survival.*Methods: Adult patients…2019 American Transplant Congress
Whole-Exome Sequencing Identifies PMS1 and DYRK1A Genes Contributing to Occurrence of Liver Cancer
Tongji hospital, Huazhong university, Organ Transplantation, Wuhan, China
*Purpose: Liver cancer is one of the most frequent cancers in China and the accurate landscape of liver cancer, especially of HBV-infected liver cancer in…2019 American Transplant Congress
Clinical Outcomes of Patients with Portal Vein Tumor Thrombi after Living Donor Liver Transplantation
Surgery, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: Patient selection criteria for living donor liver transplantation(LDLT) with hepatocellular carcinoma are generally wider than those for deceased donor liver transplantation. It is widely…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 23
- Next Page »